Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications

BACKGROUND: Entrectinib is a tropomyosin receptor kinase inhibitor approved for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours based on single-arm trials. Traditional randomised clinical trials in rare cancers are not feasible; we conducted an intrapatien...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:ESMO Open
Päätekijät: Krebs, M.G., Blay, J.-Y., Le Tourneau, C., Hong, D., Veronese, L., Antoniou, M., Bennett, I.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2021
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8103537/
https://ncbi.nlm.nih.gov/pubmed/33676294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.esmoop.2021.100072
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia